statistiche ricercatore

Continente	#
NA - Nord America	522
AS - Asia	224
SA - Sud America	131
EU - Europa	116
AF - Africa	7
Continente sconosciuto - Info sul continente non disponibili	1
OC - Oceania	1
Totale	1.002

Nazione	#
US - Stati Uniti d'America	506
BR - Brasile	122
SG - Singapore	90
CN - Cina	41
IT - Italia	37
VN - Vietnam	32
DE - Germania	16
HK - Hong Kong	12
FI - Finlandia	10
FR - Francia	10
BD - Bangladesh	9
GB - Regno Unito	9
IQ - Iraq	7
MX - Messico	6
JP - Giappone	5
RU - Federazione Russa	5
CA - Canada	4
CZ - Repubblica Ceca	4
ES - Italia	4
IN - India	4
NL - Olanda	4
PK - Pakistan	4
AR - Argentina	3
BE - Belgio	3
EC - Ecuador	3
SE - Svezia	3
TR - Turchia	3
AE - Emirati Arabi Uniti	2
AZ - Azerbaigian	2
DO - Repubblica Dominicana	2
EG - Egitto	2
JM - Giamaica	2
LB - Libano	2
LT - Lituania	2
PL - Polonia	2
UA - Ucraina	2
ZA - Sudafrica	2
AU - Australia	1
CL - Cile	1
IE - Irlanda	1
IL - Israele	1
JO - Giordania	1
KH - Cambogia	1
KZ - Kazakistan	1
LC - Santa Lucia	1
MA - Marocco	1
MD - Moldavia	1
MK - Macedonia	1
MT - Malta	1
MY - Malesia	1
NP - Nepal	1
OM - Oman	1
PA - Panama	1
PE - Perù	1
PS - Palestinian Territory	1
RS - Serbia	1
SA - Arabia Saudita	1
SN - Senegal	1
TL - Timor Orientale	1
UZ - Uzbekistan	1
VE - Venezuela	1
XK - ???statistics.table.value.countryCode.XK???	1
ZM - Zambia	1
Totale	1.002

Nome	#
Efficacy and safety of B/F/TAF in naïve people with HIV: real life data from the SHiNeSHiC research group	254
Assessing ChatGPT’s Potential in HIV Prevention Communication: A Comprehensive Evaluation of Accuracy, Completeness, and Inclusivity	153
Early treatment with low-molecular-weight heparin reduces mortality rate in SARS-CoV-2 patients	142
Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study	110
Living with HIV and Getting Vaccinated: A Narrative Review	105
New score to predict COVID-19 progression in vaccine and early treatment era: the COVID-19 Sardinian Progression Score (CSPS)	88
Viro-Immunological Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide among Women Living with HIV: A 96-Week Post-Switch Analysis from the Real-Life SHiNe-SHiC Cohort	84
Bictegravir/emtricitabine/tenofovir alafenamide in people with HIV aged ≥50: low discontinuation rates and favorable metabolic outcomes over 36 months	30
Present and future of HIV pre-exposure prophylaxis: a narrative review	26
Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV	17
Risk of autochthonous human schistosomiasis transmission in Italy	13
Totale	1.022

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	8	0	0	0	0	0	0	0	0	0	0	4	4
2022/2023	15	2	2	0	1	1	2	0	5	0	1	1	0
2023/2024	32	0	1	1	2	5	12	0	3	0	0	1	7
2024/2025	248	6	1	8	7	8	9	19	57	84	28	12	9
2025/2026	719	28	85	282	64	52	26	55	26	36	35	17	13
Totale													1.022